LISATA THERAPEUTICS, INC. 8-K

What Happened Lisata Therapeutics (LSTA) announced an amendment to its March 6, 2026 Agreement and Plan of Merger with Kuva Labs Inc. and Kuva Acquisition Corp. The Amendment moves the deadline to begin the purchaser’s tender offer from June 1, 2026 to June 10, 2026 (if the Offer starts on June 10), and extends the merger Outside Date from July 1, 2026 to July 17, 2026. The Amendment also allows Kuva to pay a non‑refundable $1,500,000 fee by one minute after 11:59 p.m. ET on July 17, 2026 to further extend the Outside Date to August 17, 2026.

Key Details

• Tender offer commencement: date by which Purchaser must start the Offer extended from June 1, 2026 to June 10, 2026 (upon commencement on June 10).
• Outside Date extended from July 1, 2026 to July 17, 2026; optional extension to August 17, 2026 if Parent pays $1,500,000 (non‑refundable) by 11:59 p.m. ET on July 17, 2026.
• Interim payments and waivers: Lisata agreed not to sue for certain claims through June 10, 2026 and will irrevocably waive claims related to Purchaser’s missed June 1 offer start if the Offer commences; Lisata will waive claims relating to a $250,000 missed May 26 interim payment if Parent pays $150,000 on June 12, 2026 and $100,000 on June 26, 2026.
• Conditions: Lisata’s waivers and covenants terminate if Parent fails to make required payments when due or materially breaches the Amendment and does not cure within two business days. Purchaser acknowledged it lacks committed financing and agreed to disclose financing status in Schedule TO and to seek alternative financing if needed.

Why It Matters This Amendment delays and conditions the timetable for the proposed acquisition, highlights financing uncertainty by acknowledging the absence of committed financing, and ties Lisata’s waivers of certain legal claims to specific payments and cure rights. For investors, the key takeaways are the extended deadlines (which postpone a potential closing), the $1.5M optional extension fee, and the reliance on Kuva’s financing arrangements — all factors that affect the likelihood and timing of the transaction. Retail shareholders should review the tender offer materials (Schedule TO) and Lisata’s solicitation/recommendation (Schedule 14D‑9) once filed for full details before deciding whether to tender shares.